NIAGEN Trademark
NIAGEN is a USPTO trademark filed by CHROMADEX, INC.. Status: Pending.
Prosecution Summary
Trademark Summary
The standard character mark NIAGEN covers active chemical ingredients for manufacturing dietary supplements, pharmaceuticals, and cosmetics in class 1; pharmaceutical preparations including nicotinamide riboside chloride injectables, nutritional supplements, and medical diagnostic kits in class 5; and goods/services across additional classes 6, 10, 18, 26, 44, 46, 51, and 52. Owned by ChromaDex, Inc., a California corporation, the application is on intent-to-use basis and currently pending with a non-final office action issued December 8, 2025, requiring applicant response. No oppositions or legal proceedings are present.
Recent Activity
Filed October 7, 2024, the application saw its first non-final office action April 16, 2025, followed by respon
Trademark Facts
| Mark | NIAGEN |
|---|---|
| Serial Number | 98788240 |
| Status | Pending |
| Filing Date | 2024-10-07 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals) |
| Owner | CHROMADEX, INC. |
| Attorney of Record | Susan M. Natland |
| Prosecution Events | 26 |
| Latest Event | XELR on 2026-03-06 |
Goods & Services
Pharmaceutical preparations, namely, nicotinamide riboside chloride for injection; pharmaceutical preparations, namely, injectable liquids for use in hydration, vitamin, healthy aging, and wellness therapies; pharmaceutical preparations, namely, injectable liquids for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, and muscle health; pharmaceutical preparations and nutritional supplements, namely, nicotinamide riboside chloride in the form of injectables; pharmaceutical preparations and nutritional supplements, namely, nicotinamide riboside chloride for use in intravenous therapy; diagnostic kits comprised of medical diagnostic assays for testing for biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits comprising diagnostic agents and preparations for medical purposes; specimen collection kits for medical purposes comprised primarily of swabs for medical purposes and also including test strips, plastic bags for transmitting medical specimens, printed mailing labels, and tubes for holding specimens; medical test kits comprised primarily of swabs, testing strips and cards for medical purposes, and also including lancets, adhesive bandages, plastic bags for transmitting medical specimens, and printed mailing labels for testing for markers in bodily fluids, liquids, saliva and tissue; diagnostic agents, preparations and substances for medical purposes; medical and veterinary diagnostic preparations and articles, namely, swabs, testing strips and cards for medical purposes for the testing of nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; diagnostic preparations and articles, namely, supplements, pharmaceutical preparations, and intravenous fluids for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; prefilled syringes and medical fluid injectors sold filled with pharmaceutical preparations; prefilled syringes and injectors filled with pharmaceutical preparations, namely, nicotinamide adenine dinucleotide precursors for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; prefilled syringes and medical fluid injectors sold filled with nicotinamide riboside chloride; nutritional supplements in the form of an injection shot; pharmaceutical preparations and nutritional supplements, namely, nicotinamide riboside chloride in the form of an injection shot; Active Chemical ingredients for use in the manufacturing of dietary supplements, nutritional products, pharmaceuticals, cosmetics, cosmetic preparations, pet products, and personal care products; chemical reagents for non-medical purposes; chemicals for use in industry and science; chemicals for use in the biochemical and chemical industry; assays for research purposes; diagnostic preparations for scientific or research use; test kits comprised of chemical preparations and reagents for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific purposes, other than for medical or veterinary use; test kits comprised of chemical agents and chemical preparations for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific purposes, other than for medical or veterinary use; specimen collection kits comprised primarily of chemically treated non-medical test strips and cards and also including, laboratory swabs, plastic bags for transmitting specimens, printed mailing labels, and tubes for holding specimens for scientific purposes, other than for medical or veterinary use; test kits for testing for markers in bodily fluids, liquids, saliva and tissue for non-medical purposes; chemical preparations and articles, namely, chemical test paper, strips, and cards for the testing of nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for scientific purposes, other than for medical or veterinary use
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-03-06 | Application Extension to Response | ELR |
| 2026-02-06 | Amendment and Mail Process Complete | AMC |
| 2026-02-05 | Change Address or Representation Form | CAR |
| 2025-12-08 | Non-Final Action | NFIN |
| 2025-10-29 | Amendment and Mail Process Complete | AMC |
| 2025-10-28 | Response to Office Action | ROA |
USPTO Refusals on Record
- multiple_class_application